Sara Bares, ACTIV 2021: Long-acting Injectable Antiretroviral Therapy for the Treatment of HIV
It was a pleasure to speak with Sara Bares (University of Nebraska, Omaha, NE, USA) to discuss long-acting injectable antiretroviral therapies for the treatment of HIV.
The abstract entitled: ‘Long Acting ART for Treatment of HIV’ was presented at the ACTHIV Virtual Conference 2021, May 20-22, 2021.
- What are the potential advantages and disadvantages of long-acting injectable (LAI) antiretroviral therapy (ART) for the treatment of HIV, compared to current treatment regimens? (0:15)
- Could you give us a brief overview of the FLAIR & ATLAS study objectives, and their findings? (2:51)
- Which patients are most likely to benefit from this regimen and in whom is it contraindicated? (4:49)
- What are the potential considerations/ challenges providers and patients may need to bear in mind before deciding to implement this regimen? (5:26)
Disclosures: Sara Bares has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the ACTHIV Virtual Conference 2021.
Share this Video
Related Videos In HIV
Jeffrey Kwong, ACTHIV 2023: Sexual health in older adults living with HIV, clinical considerations for PrEP, and HIV prevention promotion
Sexual health in the aging process is crucial for healthcare professionals to be educated on due to its significant impact on overall well-being and quality of life for older adults living with HIV. In this interview, we speak with Prof. Jeffrey Kwong (Rutgers School of Nursing, Newark, NJ, USA) to explore the importance of addressing […]
Amphotericin B, an oral lipid nanocrystal for cryptococcal meningitis, phase 2 results: David Boulware, ECCMID 2023
Intravenous amphotericin B is a mainstay of treatment in cryptococcal meningitis, in this phase 2 study the efficacy and safety of amphotericin B, a novel, orally absorbed, less-toxic formulation is investigated. It was a pleasure to talk with Prof. David Boulware (University of Minnesota, Minneapolis, USA) to learn more around the prevalence, clinical presentations and […]
Bifast study: efficacy and safety of immediate start of BIC/FTC/TAF after HIV diagnosis: Aws Waleed M. Al-Hayani, ECCMID 2023
After HIV diagnosis, antiretroviral therapy is indicated to be started as early as possible, the phase 4 Bifast study looked at the efficacy and safety of BIC/FTC/TAF when initiated at the first HIV-specialist appointment. In this interview with Dr. Aws Waleed M. Al-Hayani (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain) we discuss the controversies surrounding […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!